Rengalin oral solution, 100ml

Product description

Rengalin – a drug for the treatment of productive and unproductive cough in adults and children from 3 years of age

Composition

Active ingredients: Antibodies to bradykinin affinity purified 0.12 g*, Antibodies to histamine affinity purified 0.12 g*, Antibodies to morphine affinity purified 0.12 g** are administered as a mixture of three active aqueous dilutions of the substance, diluted respectively in 10012,10030,10050 times. Auxiliary substances: hypromellose 1.0 g, maltitol 6.0 g, glycerol 3.0 g, potassium sorbate 0.165 g, citric acid anhydrous 0.02 g, purified water up to 100 ml

Pharmacological action

It has been experimentally shown that the components of the drug modify the activity of ligand-receptor interaction of endogenous regulators with the corresponding receptors: morphine antibodies – with opiate receptors; histamine antibodies – with H1-histamine receptors; bradykinin antibodies – with B1-bradykinin receptors; at the same time, the combined use of the components leads to an increased antitussive effect. In addition to antitussive action, the complex drug due to its components has anti-inflammatory, decongestant, anti-allergic, antispasmodic (antibodies to histamine, antibodies to bradykinin) and analgesic effect (antibodies to morphine). The complex drug Rengalin by modifying histamine-dependent activation of H1 receptors and bradykinin-dependent activation of B2 receptors selectively reduces the excitability of the cough center of the medulla oblongata, inhibits the central links of the cough reflex. Inhibiting the centers of pain sensitivity in the thalamus, it blocks the transmission of pain impulses to the cerebral cortex. It inhibits the flow of pain impulses from the periphery due to a decrease in the release of tissue and plasma algogens (histamine, bradykinin, prostaglandins, etc. ). Unlike narcotic analgesics, it does not cause respiratory depression, drug dependence, and does not have narcogenic and hypnotic effects. Relieves the symptoms of acute pharyngitis, laryngitis and bronchitis, reducing bronchospasm. Relieves systemic and local symptoms of allergic reactions by affecting the synthesis and release of histamine and bradykinin from mast cells.

Indications

Rengalin is indicated for use in adults and children over 3 years of age. Productive and unproductive cough in influenza and acute respiratory viral infections, acute pharyngitis, laryngotracheitis, acute obstructive laryngitis, chronic bronchitis and other infectious and inflammatory and allergic diseases of the upper and lower respiratory tract.

Use during pregnancy and lactation

The safety of using Rengalin in pregnant women and during breastfeeding has not been studied. If you need to take the drug, the benefit-risk ratio should be taken into account.

Contraindications

Children under 3 years of age. Increased individual sensitivity to the components of the drug. Hereditary fructose intolerance (due to the presence of maltitol in the composition).

Side effects

Possible reactions of increased individual sensitivity to the components of the drug.

Interaction

In the course of the conducted clinical studies, no data were obtained on the interaction of Rengalin with drugs used as concomitant therapy.

How to take, course of use and dosage

Solution. Inside. At one time-1-2 teaspoons (5-10 ml) – outside the meal. It is advisable to keep the solution in your mouth before swallowing to maximize the effect of the drug. Apply 1-2 teaspoons 3 times a day. Depending on the severity of the condition in the first three days, the frequency of admission can be increased to 4-6 times a day. The duration of therapy depends on the severity of the disease and is determined by the attending physician.

Overdose

In case of accidental overdose, dyspeptic phenomena due to the fillers included in the preparation are possible.

Description

Colorless or almost colorless transparent liquid.

Special instructions

If necessary, it can be combined with mucolytics. Patients with diabetes should remember that each teaspoon (5 ml) of the drug contains 0.3 g of maltitol, which corresponds to 0.02 bread units (XE). Insulin is required for maltitol metabolism, although due to slow hydrolysis and absorption in the gastrointestinal tract, the need for insulin is low. The energy value of maltitol is 10 kJ or 2.4 kcal / g, which is significantly less than that of sucrose. The energy value of one teaspoon of the drug is approximately 5.7 kJ (1.37 kcal).

Form of production

Solution for oral use.

100 ml each in bottles made of OS brand glass or painted glass, sealed with lids with first opening control, with a polyethylene dropper. Each bottle together with the instructions for medical use is placed in a pack of cardboard.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf

life 3 years Do not apply after the expiration date.

Active ingredient

Antibodies

Dosage form

oral solution